Skip to main content
♕ The Globe and Mail Trade Off
Canada's free stock market contest is live! Test your investing skills for a chance to win $5,000.Enter Now!Enter Now!
➜

Cannara Biotech Inc(LOVE-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low1.780
Day High1.890
Open:1.840
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Cannara Biotech Inc

Select a category then submit the form to load news
GlobeNewswire
Cannara Announces Graduation to the Toronto Stock Exchange
GlobeNewswire
Cannara to Host Investor Webcast on February 19th, 2026
GlobeNewswire
Cannara Announces Strategic C$6.3 Million Non-Brokered Private Placement Priced at C$2.10 per Common Share 
GlobeNewswire
Cannara Announces Conditional Approval to List on the Toronto Stock Exchange
GlobeNewswire
Cannara Reports Q1 Fiscal 2026 Results, Delivers New Record Financial Results, Extends Market Share Gains and Advances Disciplined Expansion Strategy
GlobeNewswire
Cannara Achieves OTCQX Qualification and Announces Release of Fiscal Q1 2026 Financial Results on January 26, 2026
GlobeNewswire
OTC Markets Group Welcomes Cannara Biotech Inc. to OTCQX
GlobeNewswire
Cannara Achieves #1 Market Share Position in Québec as of December 2025 and Provides Update on Québec Vape Category Launch
Newsfile
Upcoming Meeting Dates - December 1, 2025
GlobeNewswire
Cannara Biotech Delivers Record Fiscal 2025 Revenue and Profitability, Achieves First Year of Positive Retained Earnings
GlobeNewswire
Cannara Biotech Inc. to Announce Fiscal Q4 2025 and Fiscal Year 2025 Financial Results on November 24, 2025 and Provides Board Update
GlobeNewswire
Cannara Announces DTC Eligibility to Facilitate U.S. Investor Access and Strengthens Balance Sheet through completion of Debt-to-Equity Conversion
GlobeNewswire
Cannara Announces Proposed Settlement of Convertible Debenture via Share Issuance
GlobeNewswire
Cannara Announces Grant of Options and RSUs
GlobeNewswire
Cannara Announces Amendment and Upsize of BMO Credit Facility to Support Facility Expansion at Valleyfield
GlobeNewswire
Cannara Biotech Delivers Highest Revenue and Profitability Since Inception in Fiscal Q3 2025
GlobeNewswire
Cannara Biotech to Host Investor Webcast on June 25th, 2025
GlobeNewswire
Cannara Reduces Cost of Debt with Lower Interest Rate and Partial Debenture Repayment; Wins 2025 Brand of the Year
INK Research
Public market insider buying at Cannara Biotech (LOVE)
Company Chart of LOVE
INK Research
Public market insider buying at Cannara Biotech (LOVE)
Company Chart of LOVE
GlobeNewswire
Cannara Biotech Delivers Record Q2 Results as National Expansion Accelerates
GlobeNewswire
Cannara Biotech Inc. to Announce Fiscal Q2 2025 Financial Results on April 28, 2025
GlobeNewswire
Cannara Biotech Announces Appointment of Justin Cohen to Board of Directors
GlobeNewswire
Cannara Biotech to Present at The Ventum Canadian Cannabis Conference on March 12th, 2025
AllPennyStocks.com
Markets are Falling, but this Cannabis Maker is Moving Higher
Markets are Falling, but this Cannabis Maker is Moving Higher
GlobeNewswire
Cannara Biotech Reports Record Q1 2025 Revenue and National Market Share, Sets Stage for Continued Momentum in 2025
GlobeNewswire
Cannara Provides Update on Its 2024 Annual General Meeting Materials amid Canada Post Strike
GlobeNewswire
Cannara Biotech to Host Investor Webcast on Thursday December 19th, 2024
GlobeNewswire
Cannara Biotech Inc. Reports Q4 and Fiscal Year 2024 Results: Achieves Record Sales Growth and Operating Cash Flow, Solidifying Leadership in Canada's Cannabis Market
AI-generated - The Globe and Mail
Cannara Biotech: Top 10 Undervalued Drug Manufacturers Industry Stocks (LOVE)
GlobeNewswire
Cannara Biotech Achieves its Highest National Market Share of 3.2% in July 2024 and Announces Investor Webcast Scheduled for August 20, 2024
GlobeNewswire
Cannara Biotech Reports Q3 2024 Financial Results

Profile

Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.